Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010–2019

Syed Shahzad Hasan; Nimrata Bal; Isabelle Baker; Chia Siang Kow; Muhammad Umair Khan

doi:10.1177/1087054721997556

Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010–2019

Syed Shahzad Hasan^*, Nimrata Bal, Isabelle Baker, Chia Siang Kow, Muhammad Umair Khan

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: We investigated the prescription trends and adverse drug reactions (ADRs) of ADHD drugs in primary care, England between 2010 and 2019. Methods: The Prescription Cost Analysis database presenting the primary care prescriptions data and the Interactive Drug Analysis Profiles presenting all suspected ADRs reported for each drug were screened. The data were analyzed using linear regression analysis to examine the annual average change per year. Results: The prescription items dispensed for ADHD showed an average 11.07% (95% CI 10.54–11.60, p =.001) increase per year and there was a mean 11.54% (95% CI 11.03–12.06, p =.001) increase per year in the costs. The overall reporting of serious and fatal ADR was reduced by 1.79% per year for ADHD drugs. Guanfacine showed a 40% mean increase per year. Conclusion: The increasing use of ADHD drugs within primary care in England could be a result of multiple factors such as growing ADHD prevalence.

Original language	English
Pages (from-to)	467-475
Number of pages	9
Journal	Journal of attention disorders
Volume	26
Issue number	3
Early online date	5 Mar 2021
DOIs	https://doi.org/10.1177/1087054721997556
Publication status	Published - 1 Feb 2022

Bibliographical note

©The Author(s) 2021. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/)

Keywords

adverse drug reactions
attention deficit hyperactivity disorder
cost
England
prescriptions

Access to Document

10.1177/1087054721997556

hasan-et-al-2021-adverse-drug-reaction-reporting-and-prescribing-trends-of-drugs-for-attention-deficit-hyperactivity
©The Author(s) 2021. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/)
Final published version, 371 KBLicence: CC BY-NC 4.0

Cite this

@article{4a9252a5adff4a0c9ad25c4307b09fa2,

title = "Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010–2019",

abstract = "Objective: We investigated the prescription trends and adverse drug reactions (ADRs) of ADHD drugs in primary care, England between 2010 and 2019. Methods: The Prescription Cost Analysis database presenting the primary care prescriptions data and the Interactive Drug Analysis Profiles presenting all suspected ADRs reported for each drug were screened. The data were analyzed using linear regression analysis to examine the annual average change per year. Results: The prescription items dispensed for ADHD showed an average 11.07% (95% CI 10.54–11.60, p =.001) increase per year and there was a mean 11.54% (95% CI 11.03–12.06, p =.001) increase per year in the costs. The overall reporting of serious and fatal ADR was reduced by 1.79% per year for ADHD drugs. Guanfacine showed a 40% mean increase per year. Conclusion: The increasing use of ADHD drugs within primary care in England could be a result of multiple factors such as growing ADHD prevalence.",

keywords = "adverse drug reactions, attention deficit hyperactivity disorder, cost, England, prescriptions",

author = "Hasan, {Syed Shahzad} and Nimrata Bal and Isabelle Baker and Kow, {Chia Siang} and Khan, {Muhammad Umair}",

note = "{\textcopyright}The Author(s) 2021. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/)",

year = "2022",

month = feb,

day = "1",

doi = "10.1177/1087054721997556",

language = "English",

volume = "26",

pages = "467--475",

number = "3",

}

TY - JOUR

T1 - Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010–2019

AU - Hasan, Syed Shahzad

AU - Bal, Nimrata

AU - Baker, Isabelle

AU - Kow, Chia Siang

AU - Khan, Muhammad Umair

N1 - ©The Author(s) 2021. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/)

PY - 2022/2/1

Y1 - 2022/2/1

N2 - Objective: We investigated the prescription trends and adverse drug reactions (ADRs) of ADHD drugs in primary care, England between 2010 and 2019. Methods: The Prescription Cost Analysis database presenting the primary care prescriptions data and the Interactive Drug Analysis Profiles presenting all suspected ADRs reported for each drug were screened. The data were analyzed using linear regression analysis to examine the annual average change per year. Results: The prescription items dispensed for ADHD showed an average 11.07% (95% CI 10.54–11.60, p =.001) increase per year and there was a mean 11.54% (95% CI 11.03–12.06, p =.001) increase per year in the costs. The overall reporting of serious and fatal ADR was reduced by 1.79% per year for ADHD drugs. Guanfacine showed a 40% mean increase per year. Conclusion: The increasing use of ADHD drugs within primary care in England could be a result of multiple factors such as growing ADHD prevalence.

AB - Objective: We investigated the prescription trends and adverse drug reactions (ADRs) of ADHD drugs in primary care, England between 2010 and 2019. Methods: The Prescription Cost Analysis database presenting the primary care prescriptions data and the Interactive Drug Analysis Profiles presenting all suspected ADRs reported for each drug were screened. The data were analyzed using linear regression analysis to examine the annual average change per year. Results: The prescription items dispensed for ADHD showed an average 11.07% (95% CI 10.54–11.60, p =.001) increase per year and there was a mean 11.54% (95% CI 11.03–12.06, p =.001) increase per year in the costs. The overall reporting of serious and fatal ADR was reduced by 1.79% per year for ADHD drugs. Guanfacine showed a 40% mean increase per year. Conclusion: The increasing use of ADHD drugs within primary care in England could be a result of multiple factors such as growing ADHD prevalence.

KW - adverse drug reactions

KW - attention deficit hyperactivity disorder

KW - cost

KW - England

KW - prescriptions

UR - http://www.scopus.com/inward/record.url?scp=85102116565&partnerID=8YFLogxK

U2 - 10.1177/1087054721997556

DO - 10.1177/1087054721997556

M3 - Article

C2 - 33666114

AN - SCOPUS:85102116565

SN - 1087-0547

VL - 26

SP - 467

EP - 475

JO - Journal of attention disorders

JF - Journal of attention disorders

IS - 3

ER -

Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010–2019

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this